Kaplan Meier survival curves for new CHIKV seropositivity during the 2- year study period from Dec 2019 – Feb 2022.
<p>Kaplan Meier survival curves for new CHIKV seropositivity during the 2- year study period from Dec 2019 – Feb 2022.</p>
Salvato in:
| Autore principale: | |
|---|---|
| Altri autori: | , , , , , , , , , , , , , , , , , , , , |
| Pubblicazione: |
2025
|
| Soggetti: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1849927642216660992 |
|---|---|
| author | Bethel Alebel Bayrau (22676588) |
| author2 | Caroline Ichura (14420100) Amna Tariq (6950915) Christabel Achieng Winter (22676591) Jael Sagina Amugongo (16679221) Victoria Atieno Okuta (22676594) Laura Wanjala Mwambingu (22676597) Kevin Onyango Ogamba (22676600) Karren Nyumbile Shaita (13046773) Charles Ochieng Ronga (22676603) Philip Chebii (6809045) Said Lipi Malumbo (16679218) Omar Katana Godana (22676606) Zainabu Jawa Jembe (22676609) Charles M. Ng’ang’a (12436719) Mwangosho Mazera Mshahame (22676612) Esra Buyukcangaz (816236) Eleonora Migliore (12596146) Donal Bisanzio (359800) Bryson Ndenga (4450168) Francis Mutuku (214961) A. Desiree LaBeaud (8319543) |
| author2_role | author author author author author author author author author author author author author author author author author author author author author |
| author_facet | Bethel Alebel Bayrau (22676588) Caroline Ichura (14420100) Amna Tariq (6950915) Christabel Achieng Winter (22676591) Jael Sagina Amugongo (16679221) Victoria Atieno Okuta (22676594) Laura Wanjala Mwambingu (22676597) Kevin Onyango Ogamba (22676600) Karren Nyumbile Shaita (13046773) Charles Ochieng Ronga (22676603) Philip Chebii (6809045) Said Lipi Malumbo (16679218) Omar Katana Godana (22676606) Zainabu Jawa Jembe (22676609) Charles M. Ng’ang’a (12436719) Mwangosho Mazera Mshahame (22676612) Esra Buyukcangaz (816236) Eleonora Migliore (12596146) Donal Bisanzio (359800) Bryson Ndenga (4450168) Francis Mutuku (214961) A. Desiree LaBeaud (8319543) |
| author_role | author |
| dc.creator.none.fl_str_mv | Bethel Alebel Bayrau (22676588) Caroline Ichura (14420100) Amna Tariq (6950915) Christabel Achieng Winter (22676591) Jael Sagina Amugongo (16679221) Victoria Atieno Okuta (22676594) Laura Wanjala Mwambingu (22676597) Kevin Onyango Ogamba (22676600) Karren Nyumbile Shaita (13046773) Charles Ochieng Ronga (22676603) Philip Chebii (6809045) Said Lipi Malumbo (16679218) Omar Katana Godana (22676606) Zainabu Jawa Jembe (22676609) Charles M. Ng’ang’a (12436719) Mwangosho Mazera Mshahame (22676612) Esra Buyukcangaz (816236) Eleonora Migliore (12596146) Donal Bisanzio (359800) Bryson Ndenga (4450168) Francis Mutuku (214961) A. Desiree LaBeaud (8319543) |
| dc.date.none.fl_str_mv | 2025-11-24T18:31:05Z |
| dc.identifier.none.fl_str_mv | 10.1371/journal.pntd.0013740.g004 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Kaplan_Meier_survival_curves_for_new_CHIKV_seropositivity_during_the_2-_year_study_period_from_Dec_2019_Feb_2022_/30697355 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Medicine Biotechnology Ecology Cancer Mental Health Infectious Diseases Virology Computational Biology epidemic arboviral prevalence prospective cohort study significant risk factors risk factors associated main risk factors associated risk factors past studies focusing high socioeconomic status although lower education year study period seropositivity among individuals two urban sites risk factors two sites socioeconomic status study period arboviral infections among adults wide risk urban settings xlink "> window screens stepwise selection sick visit seropositivity rate serologic data results showed questionnaire data past outbreaks outbreak periods older age often misdiagnosed newly exposed multivariate analysis mostly limited month intervals higher rates greater levels findings highlight febrile illness coastal site chikungunya virus blood samples asymptomatic resulting active surveillance active circulation |
| dc.title.none.fl_str_mv | Kaplan Meier survival curves for new CHIKV seropositivity during the 2- year study period from Dec 2019 – Feb 2022. |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Kaplan Meier survival curves for new CHIKV seropositivity during the 2- year study period from Dec 2019 – Feb 2022.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_a45dccf421c83eae1b3fdcad64905932 |
| identifier_str_mv | 10.1371/journal.pntd.0013740.g004 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30697355 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Kaplan Meier survival curves for new CHIKV seropositivity during the 2- year study period from Dec 2019 – Feb 2022.Bethel Alebel Bayrau (22676588)Caroline Ichura (14420100)Amna Tariq (6950915)Christabel Achieng Winter (22676591)Jael Sagina Amugongo (16679221)Victoria Atieno Okuta (22676594)Laura Wanjala Mwambingu (22676597)Kevin Onyango Ogamba (22676600)Karren Nyumbile Shaita (13046773)Charles Ochieng Ronga (22676603)Philip Chebii (6809045)Said Lipi Malumbo (16679218)Omar Katana Godana (22676606)Zainabu Jawa Jembe (22676609)Charles M. Ng’ang’a (12436719)Mwangosho Mazera Mshahame (22676612)Esra Buyukcangaz (816236)Eleonora Migliore (12596146)Donal Bisanzio (359800)Bryson Ndenga (4450168)Francis Mutuku (214961)A. Desiree LaBeaud (8319543)MedicineBiotechnologyEcologyCancerMental HealthInfectious DiseasesVirologyComputational Biologyepidemic arboviral prevalenceprospective cohort studysignificant risk factorsrisk factors associatedmain risk factorsassociated risk factorspast studies focusinghigh socioeconomic statusalthough lower educationyear study periodseropositivity among individualstwo urban sitesrisk factorstwo sitessocioeconomic statusstudy periodarboviral infectionsamong adultswide riskurban settingsxlink ">window screensstepwise selectionsick visitseropositivity rateserologic dataresults showedquestionnaire datapast outbreaksoutbreak periodsolder ageoften misdiagnosednewly exposedmultivariate analysismostly limitedmonth intervalshigher ratesgreater levelsfindings highlightfebrile illnesscoastal sitechikungunya virusblood samplesasymptomatic resultingactive surveillanceactive circulation<p>Kaplan Meier survival curves for new CHIKV seropositivity during the 2- year study period from Dec 2019 – Feb 2022.</p>2025-11-24T18:31:05ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1371/journal.pntd.0013740.g004https://figshare.com/articles/figure/Kaplan_Meier_survival_curves_for_new_CHIKV_seropositivity_during_the_2-_year_study_period_from_Dec_2019_Feb_2022_/30697355CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/306973552025-11-24T18:31:05Z |
| spellingShingle | Kaplan Meier survival curves for new CHIKV seropositivity during the 2- year study period from Dec 2019 – Feb 2022. Bethel Alebel Bayrau (22676588) Medicine Biotechnology Ecology Cancer Mental Health Infectious Diseases Virology Computational Biology epidemic arboviral prevalence prospective cohort study significant risk factors risk factors associated main risk factors associated risk factors past studies focusing high socioeconomic status although lower education year study period seropositivity among individuals two urban sites risk factors two sites socioeconomic status study period arboviral infections among adults wide risk urban settings xlink "> window screens stepwise selection sick visit seropositivity rate serologic data results showed questionnaire data past outbreaks outbreak periods older age often misdiagnosed newly exposed multivariate analysis mostly limited month intervals higher rates greater levels findings highlight febrile illness coastal site chikungunya virus blood samples asymptomatic resulting active surveillance active circulation |
| status_str | publishedVersion |
| title | Kaplan Meier survival curves for new CHIKV seropositivity during the 2- year study period from Dec 2019 – Feb 2022. |
| title_full | Kaplan Meier survival curves for new CHIKV seropositivity during the 2- year study period from Dec 2019 – Feb 2022. |
| title_fullStr | Kaplan Meier survival curves for new CHIKV seropositivity during the 2- year study period from Dec 2019 – Feb 2022. |
| title_full_unstemmed | Kaplan Meier survival curves for new CHIKV seropositivity during the 2- year study period from Dec 2019 – Feb 2022. |
| title_short | Kaplan Meier survival curves for new CHIKV seropositivity during the 2- year study period from Dec 2019 – Feb 2022. |
| title_sort | Kaplan Meier survival curves for new CHIKV seropositivity during the 2- year study period from Dec 2019 – Feb 2022. |
| topic | Medicine Biotechnology Ecology Cancer Mental Health Infectious Diseases Virology Computational Biology epidemic arboviral prevalence prospective cohort study significant risk factors risk factors associated main risk factors associated risk factors past studies focusing high socioeconomic status although lower education year study period seropositivity among individuals two urban sites risk factors two sites socioeconomic status study period arboviral infections among adults wide risk urban settings xlink "> window screens stepwise selection sick visit seropositivity rate serologic data results showed questionnaire data past outbreaks outbreak periods older age often misdiagnosed newly exposed multivariate analysis mostly limited month intervals higher rates greater levels findings highlight febrile illness coastal site chikungunya virus blood samples asymptomatic resulting active surveillance active circulation |